tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
US Market
NAMS
NewAmsterdam Pharma Company
RESEARCH TOOLSreports

NewAmsterdam Pharma Company (NAMS) Stock News & Sentiment

Compare
245 Followers
3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts
Premium
Market News
3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts
16d ago
CYTK
MNPR
NewAmsterdam Pharma: PREVAIL Parallels, Robust Trial Execution, and 2026 Milestones Support Buy Rating
Premium
Ratings
NewAmsterdam Pharma: PREVAIL Parallels, Robust Trial Execution, and 2026 Milestones Support Buy Rating
16d ago
NAMS
NewAmsterdam Pharma: Obicetrapib Momentum, 2026 Inflection Catalysts, and Undervalued Blockbuster Potential Support Buy Rating
Premium
Ratings
NewAmsterdam Pharma: Obicetrapib Momentum, 2026 Inflection Catalysts, and Undervalued Blockbuster Potential Support Buy Rating
21d ago
NAMS
NewAmsterdam Pharma: Late-Stage Obicetrapib Momentum, Regulatory Catalysts, and Strong Cash Position Underpin Buy Rating
Premium
Ratings
NewAmsterdam Pharma: Late-Stage Obicetrapib Momentum, Regulatory Catalysts, and Strong Cash Position Underpin Buy Rating
21d ago
NAMS
NewAmsterdam Pharma outlines 2026 goals after strong 2025 progress
Premium
Company Announcements
NewAmsterdam Pharma outlines 2026 goals after strong 2025 progress
21d ago
8K
NAMS
Promising Prospects for NewAmsterdam Pharma: Buy Rating on Cardiometabolic Breakthroughs and Market Potential
Premium
Ratings
Promising Prospects for NewAmsterdam Pharma: Buy Rating on Cardiometabolic Breakthroughs and Market Potential
3M ago
NAMS
Promising Outlook for NewAmsterdam Pharma: Buy Rating Supported by Favorable Market Trends and Competitive Advantages
Premium
Ratings
Promising Outlook for NewAmsterdam Pharma: Buy Rating Supported by Favorable Market Trends and Competitive Advantages
3M ago
NAMS
More NAMS News >

NAMS News on the Web

Top Executive Makes Major Move With NewAmsterdam Pharma Shares
TipRanks News
Bullish
Why NewAmsterdam Pharma Shares Are Sliding Now
TipRanks News
Neutral
Top Executive Makes Bold Move With Major NewAmsterdam Pharma Stock Sale
TipRanks News
Bullish
Why NewAmsterdam Pharma Shares Are Under Pressure
TipRanks News
Bullish
3 ‘Strong Buy’ Stocks to Buy Today, 1/14/2026, According to Top Analysts
TipRanks News
Bullish
Analysts Have Conflicting Sentiments on These Healthcare Companies: Bicara Therapeutics Inc. (BCAX), NewAmsterdam Pharma Company (NAMS) and GE Healthcare Technologies Inc (GEHC)
TipRanks News
Bullish
NewAmsterdam Pharma: PREVAIL Parallels, Robust Trial Execution, and 2026 Milestones Support Buy Rating
TipRanks News
Bullish
NewAmsterdam Pharma: Obicetrapib Momentum, 2026 Inflection Catalysts, and Undervalued Blockbuster Potential Support Buy Rating
TipRanks News
Bullish

News Score - Last 7 Days

Positive
NAMS
Sector Average
Media Buzz
This Week3 articles
Weekly Average3.5 articles
News Sentiment
This Week100%
Sector Average75%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is NAMS’s Media Buzz Sentiment?
3 articles about NAMS were published this week. In an average week, 3.5 articles are published.
    What is NAMS’s weekly average amount of articles?
    In an average week, 3.5 articles about NAMS are published.
      What is NAMS’s News Sentiment?
      100% of articles about NAMS were positive this week, compared to its sector average of 75%.
        Healthcare Stocks that are Trending in the News
        CBLControl Bionics Ltd.
        CRDFCardiff Oncology
        KRROKorro Bio
        IMAImageneBio
        VREOFVireo Growth
        Showing the stocks with the most bullish news sentiment over the past week